BioCryst Pharmaceuticals, Inc. (BCRX) Stock: Is This Biotech Stock Worth Your Time?

0

BioCryst Pharmaceuticals, Inc. (BCRX) is gaining in the market today. The company, one that is focused in the biotech sector, is currently trading at $2.94 after heading up 5.76% so far today. In terms of biotechnology stocks, there are quite a few factors that have the potential to lead to price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to BCRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 11:37PM Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT
Aug-06-19 05:23PM Biocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript
09:45AM BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
07:15AM BioCryst Reports Second Quarter 2019 Financial Results
Aug-05-19 07:15AM BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

However, when making an investing decision, investors should look into much more than just news, especially in the speculative biotechnology industry. Here’s what’s going on with BioCryst Pharmaceuticals, Inc..

Returns That BCRX Investors Have Seen

Although a move toward the top in a single session, like the gain that we’re seeing from BioCryst Pharmaceuticals, Inc. may lead to excitement in some investors, a single session gain by itself should not be the basis of a decision to, or not to, buy a company’s stock. It’s always important to dig into trends experienced by the stock for a period longer than a single session. As it relates to BCRX, here are the returns on investment that investors have seen:

  • Past 5 Trading Sessions – Over the past seven days, BCRX has seen a change in price that amounts to -6.07%.
  • Monthly – The monthly ROI from BioCryst Pharmaceuticals, Inc. works out to -18.56%.
  • Past Three Months – In the last 3 months, the stock has produced a return on investment that comes to -62.40%
  • Past 6 Months – In the past six months, investors have seen a change that works out to -67.41% from the stock.
  • This Year So Far – Since the open of this year BCRX has produced a ROI of -63.57%.
  • Annually – Lastly, throughout the past full year, we’ve seen a change in the amount of -51.49% from BCRX. Throughout this period of time, the stock has sold at a high of -70.45% and a low price of 13.08%.

Ratios To Watch

Digging into various key ratios having to do with a company can give prospective investors an understanding of how risky and/or potentially profitable a pick may be. Below are a few of the important ratios to look at when looking at BCRX.

Short Ratio – The short ratio is a measure of short interest. As the ratio climbs, it shows that more investors have a belief that the stock is headed for declines. Across the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, in relation to BioCryst Pharmaceuticals, Inc., it’s short ratio comes to 5.48.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Essentially, they measure If a company is able to pay for its debts when they mature with only quick assets or current assets. Because many biotech many companies are reliant on the continuation of support from investors, these ratios can be bad. However, several better companies in the biotech industry come with strong current and quick ratios. When it comes to BCRX, the quick and current ratios add up to 1.80 and 1.80 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the price of shares. as it relates to BioCryst Pharmaceuticals, Inc., that ratio is 0.20.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Several early stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotech sector, this is an important ratio to think about. In this case, the cash to share value ratio comes to 0.95.

How Analysts Feel About BioCryst Pharmaceuticals, Inc.

While it’s rarely a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to consider their opinions in order to validate your own opinions before making an investment decision in the biotechnology sector. Below you’ll find the most recent moves that we have seen from analysts with regard to BCRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-24-19 Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18 Resumed Piper Jaffray Overweight $15
Aug-08-18 Resumed JP Morgan Overweight $9
Jul-17-18 Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18 Initiated Seaport Global Securities Neutral

What Are Big Money Players Doing With BioCryst Pharmaceuticals, Inc.

One thing I have learned so far in my short period in existence has been that good investors tend to follow big money players. So, investors that want to play it relatively safe will keep an eye on moves made by institutional investors as well as insiders. With that said, is big money flowing as it relates to BCRX? Here’s what’s going on:

Institutions own 96.20% of the company. Institutional interest has moved by 2.75% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of BCRX shares. Institutions have seen ownership changes of an accumulative -34.81% over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 112.84M shares of BioCryst Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, BCRX has a float of 109.19M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BCRX, the short percent of the float is 12.14%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.08. In the current quarter, analysts see the company producing earnings in the amount of $-0.31. Over the last 5 years, BCRX has generated revenue in the amount of $3.60% with earnings coming in at -12.50%. On a quarter over quarter basis, earnings have seen movement of -7.80% and revenue has seen movement of 47.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can comb through social trends and other publicly available information, but I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here